Department of Surgery, Wenzhou Medical University, Wenzhou City, P.R. China.
Department of Surgery, Zhejiang Medical College, Hangzhou City, P.R. China.
Turk J Med Sci. 2017 Apr 18;47(2):658-667. doi: 10.3906/sag-1601-198.
BACKGROUND/AIM: Dendritic cell-based vaccine therapy for renal cell carcinoma is effective but requires improvement. Here we explored whether combination therapy with dendritic cell-based vaccine and anti-CD69 antibody can enhance antitumor efficacy in renal cell carcinoma-bearing mice.
Balb/c mice were challenged subcutaneously with murine renal cell carcinoma (Renca) cells. On day 3 after tumor cell inoculation, tumor-bearing mice either were left untreated or were treated with Renca tumor lysate-pulsed dendritic cells (i.e. dendritic cell-based vaccine), anti-CD69 antibody, or a combination of Renca tumor lysate-pulsed dendritic cells with anti-CD69 antibody. The mice were sacrificed on day 28. Tumor volume was measured for analysis of antitumor efficacy. Spleens were excised to evaluate antitumor immunological responses by measuring the proliferation and activation of T cells, which have the capacity to recognize and destroy tumor cells.
Combination treatment with Renca tumor lysate-pulsed dendritic cells and anti-CD69 antibody resulted in significant decreases in tumor volume and significant increases in T-cell proliferation and activity, compared with no treatment or either treatment alone.
These findings indicate that anti-CD69 antibody can potentiate antitumor efficacy of dendritic cell-based vaccine. The augmented therapeutic efficacy conferred by the combination therapy may be associated with increased T-cell proliferation and activity.
背景/目的：树突状细胞为基础的肾癌疫苗治疗是有效的，但需要改进。在这里，我们探讨了树突状细胞为基础的疫苗与抗 CD69 抗体联合治疗是否可以增强荷肾细胞癌小鼠的抗肿瘤疗效。
Balb/c 小鼠皮下接种小鼠肾细胞癌（Renca）细胞。在肿瘤细胞接种后第 3 天，荷瘤小鼠或不治疗或用 Renca 肿瘤裂解物脉冲树突状细胞（即树突状细胞疫苗）、抗 CD69 抗体或 Renca 肿瘤裂解物脉冲树突状细胞联合抗 CD69 抗体治疗。第 28 天处死小鼠。测量肿瘤体积以分析抗肿瘤疗效。切除脾脏以通过测量 T 细胞的增殖和激活来评估抗肿瘤免疫反应，T 细胞具有识别和破坏肿瘤细胞的能力。
与未治疗或单独治疗相比，Renca 肿瘤裂解物脉冲树突状细胞和抗 CD69 抗体联合治疗导致肿瘤体积显著减小，T 细胞增殖和活性显著增加。
这些发现表明抗 CD69 抗体可以增强树突状细胞为基础的疫苗的抗肿瘤疗效。联合治疗赋予的增强治疗效果可能与 T 细胞增殖和活性增加有关。
